FDA Demands More Information For Amneal Parkinson’s Disease Drug
IPX203 Candidate Is ‘A Much Better Product’ Than Predecessor Rytary
Amneal says it will work closely with the FDA after seeing its application for the company’s IPX203 cardbidopa/levodopa extended-release turned down for approval by the agency.
